Biosight
Innovative cancer therapeutics
Total raised
€29M
€28,672,380
Funding rounds
2
Investors
4
distinct backers
Active since
2016-04
latest 2020-11
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood21
base rate 51% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood13
base rate 12% (2+ rounds)
- ▲ 27y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-11-03 | Series C | €17M | Israel Biotech Fund | View deal → |
| 2016-05-01 | Growth/Late | €12M | Arkin Holdings,Michael Ilan Management and Investments,Primera Capital | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Trax€791MIsrael · Software
- Oura Health€779MFinland · Healthtech